The abstract is read at the publisher; the summary is JClub's.
WHO established the first International Standard for CHIKV-specific neutralising antibodies, assigning 1502/19 a potency of 1000 International Unitage/mL after harmonising results across 26 labs.
- Why it matters: Neutralisation titres to chikungunya virus vary widely between assays, limiting comparability of results from natural infection and different vaccines and slowing efforts to define protection-linked antibody levels.
- What they did: In an international 2019–20 study, 26 laboratories in 12 countries tested two candidate standards (1502/19 and 1504/19) using multiple virus-neutralisation assays and immunoassays, then estimated mean and relative potencies statistically.
- The result: Both candidates were consistently detected and showed near-identical overall mean potencies (1502/19: 3·44 log10; 1504/19: 3·48 log10), and expressing titres relative to the standards substantially reduced assay variability.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.